2026-10-12T05:32:24Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33736159 2026-09-14T12:24:46Z category_27061 item_type_3 month_year_09_2026

Supplementary Material: Pre-conception GLP-1/GIP receptor agonist use is associated with lower risks of adverse pregnancy and cardiometabolic outcomes in patients with polycystic ovarian syndrome Alex E. Henney (20380336) Phoebe J Holmes (24882601) David R. Riley (15096959) Megan Heague (23930146) Dharani K Hapangama (10805345) Uazman Alam (719195) Daniel J Cuthbertson (7371137) Major global burdens of disease PCOS <p dir="ltr">This study uses a large, multinational real-world dataset to evaluate associations between preconception GLP-1/GIP receptor agonist therapy and adverse pregnancy and long-term cardiometabolic outcomes in women with polycystic ovary syndrome (PCOS). Compared with metformin, preconception GLP-1/GIP receptor agonist use was associated with lower risks of adverse pregnancy outcomes, type 2 diabetes and major adverse cardiovascular events, supporting further investigation of preconception metabolic optimisation in PCOS.</p> 2026-09-14T12:24:46Z Dataset Dataset 10.6084/m9.figshare.33736159.v1 https://figshare.com/articles/dataset/Supplementary_Material_Pre-conception_GLP-1_GIP_receptor_agonist_use_is_associated_with_lower_risks_of_adverse_pregnancy_and_cardiometabolic_outcomes_in_patients_with_polycystic_ovarian_syndrome/33736159 CC BY 4.0